Sectors
CCCC
C4 Therapeutics, Inc.
3.77
3 x 3.72
7 x 3.74
bid
ask
-
0.06
1.66%
10:00 AM
timesize
| Ytd | 97.19% | |
| 1y | 69.66% |
3.76
day range
3.95
1.69
52 week range
5.17
| Open | 3.80 | Prev Close | 3.83 | Low | 3.76 | High | 3.95 | Mkt Cap | 317.23M |
| Vol | 285.22K | Avg Vol | 3.19M | EPS | -1.19 | P/E | -3.22 | Forward P/E | -2.37 |
| Beta | 2.90 | Short Ratio | 7.10 | Inst. Own | 91.47% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 3.87 | 200-d Avg | 2.81 | 1yr Est | 15.00 |
| Income Statement | |||
| Total Revenue | 6.15M | ||
| Revenues (USD) | 6.15M | ||
| Gross Profit | 6.15M | ||
| Operating Expenses | 33.94M | ||
| Research and Development Expense | 24.61M | ||
| Selling, General and Administrative Expense | 9.33M | ||
| Operating Income | -27.78M | ||
| Net Income | -25.13M | ||
| Net Income Common Stock | -25.13M | ||
| Net Income Common Stock (USD) | -25.13M | ||
| Consolidated Income | -25.13M | ||
| Earnings per Basic Share | -0.20 | ||
| Earnings per Basic Share (USD) | -0.20 | ||
| Earnings per Diluted Share | -0.20 | ||
| Earning Before Interest & Taxes (EBIT) | -25.13M | ||
| Earning Before Interest & Taxes (USD) | -25.13M | ||
| Weighted Average Shares | 126.07M | ||
| Weighted Average Shares Diluted | 126.07M | ||
| Balance Sheet | |||
| Cash and Equivalents | 64.72M | ||
| Cash and Equivalents (USD) | 64.72M | ||
| Investments | 207.00M | ||
| Investments Current | 174.40M | ||
| Investments Non-Current | 32.60M | ||
| Trade and Non-Trade Receivables | 2.88M | ||
| Current Assets | 245.37M | ||
| Property, Plant & Equipment Net | 43.58M | ||
| Total Assets | 328.86M | ||
| Debt Current | 6.52M | ||
| Total Debt | 58.45M | ||
| Current Liabilities | 27.25M | ||
| Debt Non-Current | 51.93M | ||
| Total Liabilities | 94.61M | ||
| Accumulated Retained Earnings (Deficit) | -763.82M | ||
| Accumulated Other Comprehensive Income | -322.00K | ||
| Shareholders Equity | 234.25M | ||
| Shareholders Equity (USD) | 234.25M | ||
| Assets Non-Current | 83.49M | ||
| Total Debt (USD) | 58.45M | ||
| Deferred Revenue | 25.56M | ||
| Liabilities Non-Current | 67.36M | ||
| Trade and Non-Trade Payables | 773.00K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 1.85M | ||
| Net Cash Flow from Financing | 462.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -13.33M | ||
| Capital Expenditure | -64.00K | ||
| Issuance (Purchase) of Equity Shares | 406.00K | ||
| Net Cash Flow from Investing | 16.15M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 16.22M | ||
| Net Cash Flow from Operations | -29.94M | ||
| Share Based Compensation | 2.67M | ||